165 related articles for article (PubMed ID: 27194138)
1. [IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].
Pilz K; Jentsch C; Krause M
Strahlenther Onkol; 2016 Jun; 192(6):428-30. PubMed ID: 27194138
[No Abstract] [Full Text] [Related]
2. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
3. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
4. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
[TBL] [Abstract][Full Text] [Related]
5. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.
Alonso C; Dutta SW; Mitra N; Landsburg DJ; Zaorsky NG; Grover S; Peterson J; Trifiletti DM
Cancer Med; 2018 Apr; 7(4):1118-1126. PubMed ID: 29479868
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.
McKay P; Fielding P; Gallop-Evans E; Hall GW; Lambert J; Leach M; Marafioti T; McNamara C;
Br J Haematol; 2016 Jan; 172(1):32-43. PubMed ID: 26538004
[No Abstract] [Full Text] [Related]
7. The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database.
Wang S; Jia M; Han J; Zhang R; Huang K; Qiao Y; Chen P; Fu Z
Cancer Med; 2021 Jan; 10(2):540-551. PubMed ID: 33249743
[TBL] [Abstract][Full Text] [Related]
8. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
9. Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study.
Wilson MR; Bagguley T; Smith A; Roman E; Patmore R; Hanlon K; Leach M; Bishton M; Burton C; McKay P
Br J Haematol; 2019 Sep; 186(6):e214-e217. PubMed ID: 31344253
[No Abstract] [Full Text] [Related]
10. [Hodgkin lymphoma (Hodgkin disease)].
Naumann UK; Käser L; Vetter W
Praxis (Bern 1994); 2006 Nov; 95(44):1697-703; quiz 1704, 1706. PubMed ID: 17111877
[No Abstract] [Full Text] [Related]
11. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
13. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
[TBL] [Abstract][Full Text] [Related]
14. Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Rana S; Holland J
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):547-548. PubMed ID: 29413265
[No Abstract] [Full Text] [Related]
15. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
[TBL] [Abstract][Full Text] [Related]
16. An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma ("Poppema Lennert" lymphoma).
Ben Rejeb S; Dhaoui A; Ben Ghachem D; Jomni T; Abouda M; Abouda M; Turki S; Bellil K
Tunis Med; 2016 Feb; 94(2):159-61. PubMed ID: 27532537
[No Abstract] [Full Text] [Related]
17. Modern management of lymphocyte-predominant Hodgkin lymphoma.
Xing KH; Savage KJ
Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
[TBL] [Abstract][Full Text] [Related]
18. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
Olszewski AJ; Shrestha R; Cook NM
Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
[TBL] [Abstract][Full Text] [Related]
19. Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation?
Szychot E; Shankar A; Haider A; Ramsay A
Br J Haematol; 2018 May; 181(3):403-406. PubMed ID: 28369705
[No Abstract] [Full Text] [Related]
20. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
